New breast scan could rival MRI for detecting tumors
NCT ID NCT05754749
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This pilot study compares contrast-enhanced digital breast tomosynthesis (CE-DBT) to standard MRI in 20 women with known breast lesions. Researchers want to see if CE-DBT can give doctors similar confidence in identifying suspicious areas. If it works, it might offer a quicker or more comfortable option for some patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iohexol (contrast agent)
- What this could lead to
- If successful, CE-DBT could become a more accessible or faster alternative to MRI for evaluating breast lesions, potentially improving diagnosis.
- What could go wrong
- This is a very early pilot study with only 20 participants, so results may not apply broadly. The new method may not match MRI's accuracy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?